Regenerative medicine specialistCollPlant(NASDAQ: CLGN) has revealed that the 3D bioprinted breast tissues it’s developing are set to enter animal trials in the very near future.
Alongside the release of its FY 2021 results, which show that it generated $15.6 million in revenue, 155.7% more than the $6.1 million it reported in FY 2020, CollPlant announced that its bioprinted implants will enter in-vivo testing from Q2 2022.
These grafts, which the firm is considering putting into large-scale production using BICO firm CELLINK’s machines, are designed to gradually degrade and be replaced by native tissues, in a safer alternative to breast augmentation procedures. With further R&D, CollPlant believes that its implants could be deployed in up to 2.2 million surgeries, enabling it to address a market worth an estimated $2.8 billion.
Collplant首席执行官Yehiel Tal说：“在未来的一年中，我们预计我们的一些领先计划将达到发展里程碑，包括开始了3D生物打印的再生乳房植入计划的大型动物研究。”“我们还随着3D生物打印应用的生物企业的开发以及可光化的真皮填充剂的发展，我们也在继续进步。”
Collplant的2021财年财务
Although CollPlant hasn’t provided a division-by-division breakdown of its annual revenue, it’s clear from what has been revealed, that its rate of growth is beginning to accelerate. In large part, the firm’s rapid rise in revenue last year was down to a1.03亿美元的生物打印合同它与AbbViecompanyAllergan美学在2021年3月。
As part of this agreement, the latter has begun to use CollPlant’s artificial collagen to create dermal and soft tissue fillers, and it could go on to develop two more products in future. The deal has also seen CollPlant receive an initial $14 million, and while this represented 90% of its FY 2021 revenue, it could gain another $89 million in milestone payments should any of Allergan Aesthetics’ products make it to market.
In addition to generating more revenue in FY 2021 than FY 2020, the company improved its profitability as well, raising its gross profit from $3.1 million to $13.6 million. This was primarily due to the fact that over this period, its cost of revenue fell from $3 million to $2 million, owing to expenses related to royalties, bio-ink and rhCollagen sales, and the ending of its deal withUnited Therapeuticsin FY 2020.
Thanks largely to a registered direct offering in February 2021, which saw it raise $31.8 million in net proceeds and $6 million from the exercise of warrants, CollPlant was able to attract $38.8 million in financing across last year. As it happens, some $31.6 million of this funding was deployed immediately in short-term cash deposits, the likes of which generated up to $172,000 for the firm in FY 2020.
| Collplant Financials（$） | FY 2020 | FY 2021 | Difference (%) | FY 2019 | FY 2021 | Difference (%) |
| Revenue | 6.1m | 15.6m | +155.7 | 2.3m | 15.6m | +578.3 |
| Cost of Revenue | 3m | 2m | -33 | 1.9m | 2m | +5.3 |
| 毛利 | 3.1m | 13.6m | +338.7 | 0.4m | 13.6m | +3300 |
| Net Cash From Financing Activities | 4.5m | 3880万 | +762.2 | 5.4m | 3880万 | +618.5 |
| E.O.Y Cash Balance | 3.5m | 13.4m | +282.3 | 4m | 13.4m | +235 |
CollPlant’s breast implant trials
自宣布创建它首先再生乳房植入物2019年，该公司稳步寻求提高其临床和商业生存能力。这些组织本身是由患者脂肪细胞和ECM成分以及“ Rhcollagen”套管胶植物植物生长的动物或尸体胶原蛋白的替代品制成的。
In theory, once these grafts are injected into patients’ tissues, they foster the regeneration of native cells before slowly degrading, leaving behind no foreign contaminants. CollPlant says this procedure could offer a “revolutionary alternative” to silicone implants or fat transfer operations which come with a ‘risk of adverse events,’ but they aren’t yet ready for market, and continue to undergo clinical trials.
One way the company has sought to accelerate the development of its bioprinted breast implants is via its recently-establishedpartnership with CELLINK。上个月宣布合作时，Collplant表示，Cellink的“高通量生物生产者”和专业知识可以使其能够克服面临植入物可扩展性的障碍。
That being said, the firm has also worked with3D系统before to developbreast reconstruction treatmentsfor cancer survivors, and it’s possible that its current work will allow it to build on some of the findings it made as part of this project too.
In the case of its newly-announced trials, CollPlant has let little slip about their exact set up, but they’re understood to offer an opportunity to put its learnings from preclinical studies into practice, while taking a significant step forward in its breast implants’ R&D, in that their viability will now be tested in-vivo at scale.
Advances in breast implant bioprinting
Even though 3D bioprinting itself remains an emerging technology, a significant amount of progress has already been made in using it to produce viable breast implants. Earlier this year,愈合形状向其研发筹集了680万美元patient-specific breast tissues,旨在治疗接受乳房切除术的人。
在过去，plcoskin还宣布了与之合作的计划Yonsei University和LipoCoatwith the aim of coming up with anovel 3D printed breast implant。In essence, the project was set up to combine LipoCoat’s lipid film coating technology and Plcoskin’s PCL-collagen coating approach, as a means of developing a uniquely-glazed graft that offers a reduced risk of infection or rejection.
Elsewhere, similar technologies are being developed to create all sorts of other tissues as well, ranging from the3D生物打印的人tescticle在University of British Columbia, to thebioprinted liver tissues的T&R Biofab。
To stay up to date with the latest 3D printing news, don’t forget to subscribe to the3D打印行业newsletteror follow us onTwitter或喜欢我们的页面Facebook。
For a deeper dive into additive manufacturing, you can now subscribe to ourYoutubechannel, featuring discussion, debriefs, and shots of 3D printing in-action.
Are you looking for a job in the additive manufacturing industry? Visit3D Printing Jobsfor a selection of roles in the industry.
特征图显示了由胶结植物生产的3D生物打印乳房植入物。摄影由Valerie Arad，coldplant。
